Insider · CIK 0001816194
Matthew Gall
Files at KLRS (Kalaris Therapeutics, Inc.), ITOS (iTeos Therapeutics, Inc.), TNGX (Tango Therapeutics, Inc.). First filing Nov 19, 2024, latest Nov 19, 2024.
Matthew Gall files SEC Form 4 as CFO at ITOS (iTeos Therapeutics, Inc.), and also at KLRS (Kalaris Therapeutics, Inc.), TNGX (Tango Therapeutics, Inc.). Since Nov 19, 2024, Matthew Gall has reported 1 open-market buy worth $39k and 0 open-market sells worth $0, the latest filed on Nov 19, 2024.
A track record needs three past buys with six months of prices behind them; Matthew Gall has 0, so none is measured yet.
The newest scored trade: bought $39k of ITOS on Nov 19, 2024, filed Nov 19, 2024, scored 31 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | ITOSbuy iTeos Therapeutics, Inc. | $39k 5,000 shares | +8% | - |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | TNGX Tango Therapeutics, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 40,000 | May 5, 2026 |
| May 1, 2026 | TNGX Tango Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +240,000 | $0.00 | $0 | 240,000 | May 5, 2026 |
| Mar 19, 2026 | KLRS Kalaris Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +95,000 | $0.00 | $0 | 95,000 | Mar 20, 2026 |
| Nov 3, 2025 | KLRS Kalaris Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +235,000 | $0.00 | $0 | 235,000 | Nov 3, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | UTender of shares Common Stock | -89,429 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,063 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -135,937 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,388 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,123 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -252,135 | - | - | 0 | Aug 29, 2025 |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 89,429 | Mar 11, 2025 |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Mar 11, 2025 |
| Nov 19, 2024 | ITOS iTeos Therapeutics, Inc. | POpen-market purchase Common Stock | +5,000 | $7.73 | $39k | 65,429 | Nov 19, 2024 |
Questions about Matthew Gall
Answered from the filings on this page, as of the latest one.
Is Matthew Gall buying or selling?
Not in the last 12 months. Matthew Gall's latest open-market trade on SEC Form 4 was bought $39k of ITOS on Nov 19, 2024.
How did Matthew Gall's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Gall has 0.
Where does Matthew Gall file Form 4?
Matthew Gall has filed Form 4 at ITOS (iTeos Therapeutics, Inc.) as Chief Financial Officer; KLRS (Kalaris Therapeutics, Inc.) as Chief Financial Officer; TNGX (Tango Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.